CEMBO aims at developing Excellence in the Research Area of Combating and Evaluation of Mixed Biofilms.
This will be achieved by twinning the Comenius University in Bratislava (CU), Faculty of Natural Sciences (FNS) with outstanding EU institutions with high expertise in the areas of anti-biofilm strategies and biofilm visualization. The team from FNS CU has an established scientific reputation and has exploited its expertise in the development of novel future technologies.
The goal of the CEMBO project is to provide CU with the opportunity to learn from partners, strengthen the research potential on CU with emphasis on building a Centre of Excellence in the field, concerning different aspects of mixed biofilms spanning from basic research over the dissemination of knowledge to possible applications in industry.
CEMBO will allow the excellence development required for a consolidated strategic research approach and designing a set of guidelines including methodological route implemented through scientific events leading to exploitation and commercialization of the results that will have a strong regional, national, and European impact.
The objectives are in line with the specific challenge and scope of the topic H2020-WIDESPREAD-2020 of the Twinning call, addressing networking gaps and deficiencies between the research institutions of the Widening countries and internationally-leading counterparts at the EU level. This challenge is addressed by twinning CU with 2 leading EU research institutions: Amsterdam University Medical Centers (Amsterdam UMC), location Academic Medical Center (AMC), Netherlands, a global leader in the development and invention of novel antimicrobial strategies to combat biomaterial-associated infections; Charité Universitätsmedizin Berlin (CHAR), Germany, one of the largest and most prestigious university hospitals in Europe, is home to the Biofilmcenter, a laboratory internationally-recognized for its excellence in the field of diagnostics in biofilm infections.
